Condition: Prostate Cancer · Localized Prostate Carcinoma · Sponsor: Baptist Health South Florida
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
This description comes directly from the study's public registry record.
Rohan Garje, M.D. · 786-596-2000 · rohan.garje@baptisthealth.net
Always discuss trial participation with your own doctor first.
| Miami Cancer Institute at Baptist Health, Inc. | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07455903